Targeting the eicosanoid pathway in non-small-cell lung cancer

Leora Horn, Michael Backlund, David H. Johnson

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E2 (PGE2), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.

Original languageEnglish (US)
Pages (from-to)675-688
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Issue number6
StatePublished - Jun 2009


  • Cyclooxygenase-2
  • Eicosanoids
  • Non-small-cell lung cancer
  • Prostaglandin E

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Targeting the eicosanoid pathway in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this